期刊文献+

黄葵胶囊对原发性微小病变型肾病患者hCRP及Hcy的影响 被引量:2

下载PDF
导出
摘要 有研究表明高敏C反应蛋白(hs-CRP)在动脉粥样硬化发生、发展中起重要作用[1],高水平同型半胱氨酸(Hcy)则是心血管疾病的独立危险因素[2,3],而在慢性肾脏病中两者之间的关系尚未明确,本文拟观察黄葵胶囊对原发性微小病变型肾病(MCD)患者hCRP及Hcy的影响,探讨其可能的治疗机制。
作者 朱宏
出处 《中国中西医结合肾病杂志》 2013年第2期169-170,共2页 Chinese Journal of Integrated Traditional and Western Nephrology
  • 相关文献

参考文献9

  • 1Hackam DG, Anand SS. Emerging risk factors for atherosclerotie vascular disease:a critical review of the evidence. JAMA,2003, 290 (7) :932 - 940.
  • 2E1 - Oudi M, Aouni Z, Mazigh C, et al. Total homocysteine levels and cardiovascular risk factors in healthy Tunisians. East Medi- terr Health J,2011,17(12) :937 -942.
  • 3Veeranna V, Zalawadiya SK, Niraj A, et al. Homocysteine and re- classification of cardiovascular disease risk. J Am Coil Cardiol, 2011,58(10) :1025 - 1033.
  • 4杨照勇,荣海钦.C反应蛋白与代谢综合征[J].国外医学(内分泌学分册),2004,24(3):173-175. 被引量:58
  • 5Baer PC,Gauer S, Wegner B, et al. C - reactive protein induced activation of MAPK and RANTES in human renal distal tubular epithelial cells in vitro. Clin Nephro1,2008,66( 3 ) : 177 - 183.
  • 6Foucher C, Brugere L, Ansquer JC. Fenofibrate, homocysteine and renal function. Curt Vasc Pharmaco1,2010,8 (5) :589 - 603.
  • 7Atamer A, Kocyigit Y, Ecder SA, et al. Effect of oxidative stress on antioxidant enzyme activities, homocysteine and lipoproteins in chronic kidney disease. J Nephrol,2008,21 (6) :924 -930.
  • 8杜先凤,高渝.黄葵胶囊联合小剂量雷公藤多苷治疗糖尿病肾病蛋白尿的疗效观察[J].中国中西医结合肾病杂志,2011,12(9):822-823. 被引量:9
  • 9邓声莉,杨敬华.黄葵胶囊治疗原发性肾病综合征临床分析[J].中国中西医结合肾病杂志,2010,11(6):540-541. 被引量:4

二级参考文献31

  • 1刘晓刚,刘素雁.黄葵胶囊对实验性肾病综合征的疗效观察和机制探讨[J].哈尔滨医科大学学报,2005,39(4):352-354. 被引量:19
  • 2邹洪斌,张立,杨立志.黄葵胶囊治疗糖尿病肾病的临床疗效观察[J].现代预防医学,2006,33(11):2197-2198. 被引量:15
  • 3王海燕.肾脏病学[M].北京:人民卫生出版社,1998.877-878.
  • 4李葆青.湿热、淤血与慢性肾衰病症关系评述[J].中华中医药杂志,2005,20(10):25-29.
  • 5Locatelli F,Canaud B,Eckardt KU,et al.The importance of dia2betic nephropathy in current nephrological practice.Nephrol Dial Transpl,2003,18(9):1716.
  • 6Caramori ML,Mauer M.Diabetes and nephropathy.Curr OpinNephrol Hy,2003,12(3):273.
  • 7Weyer C, Yudkin JS, Stehouwer CD, et al. Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis,2002,161:233-242.
  • 8Daniel G, Hackam MD, Sonia S. Emerging risk factors for atherosclerotic vascular disease. JAMA, 2003,290: 932-939.
  • 9Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation, 2002,105:1890-1896.
  • 10Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Eng J Med,2002,347,1557-1564.

共引文献68

同被引文献14

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部